Q3 2026 Thyrocare Technologies Ltd Earnings Call Transcript
Key Points
- Thyrocare Technologies Ltd (BOM:539871) reported a consolidated revenue growth of 18% year-on-year, driven primarily by a 20% increase in the pathology business.
- The company achieved a significant milestone by becoming India's first and only 100% NABL accredited national laboratory chain, underscoring its commitment to quality.
- Thyrocare's franchisee base reached its highest level ever, with 10,300 active quarterly franchisees, reflecting strong brand equity and market demand.
- The company expanded its test menu and consumer offerings, including the launch of a 100+ SKU menu for tests based on the Phadia platform.
- Internationally, Thyrocare's business in Tanzania delivered 140% year-on-year revenue growth, with expectations to reach operating break-even in the next 12 to 18 months.
- Despite the overall growth, the radiology business underperformed, pulling down the consolidated growth rate to 18%.
- The Vimta business experienced a decline due to tightened credit policies, impacting overall revenue growth.
- The company faced softer demand during the quarter due to festivals and seasonality, affecting growth momentum.
- There was a notable decrease in revenue per test, attributed to heavy discounting on certain tests like sugar tests.
- The company anticipates that sustaining a 15-16% growth rate will come at a cost, potentially impacting future margin improvements.
Ladies and gentlemen, good day and welcome to the Thyrocare Q3 FY26 conference call hosted by Thyrocare Technologies Limited. (Operator Instructions) Please note that this call is being recorded.
I now hand the conference over to Mr. Preet Joshi from Thyrocare.
Thank you and over to you.
Over to you. You may go ahead please.
Thank you. A very good evening to all, and thank you for joining us today for the Thyrocare earning conference call for the third quarter of FY 2026.
Today we have with us Mr. Rahul Guha. Are we audible?
Yes, you are. Please go ahead.
I'm able -- yes, you're audible. Please go ahead.
Hello.
Sir, we can hear you. You may go ahead please.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
